Brenda Ernst, MD
Hematology & Oncology · Scottsdale, AZNPI 1134449416
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,810 of the $4,310 with a category attached, or 88.4%. Gilead accounts for 90.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $3,963 and has fallen 95.7% since, to $168 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 14 payments — averaging $307.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- AstraZeneca$107
- Stemline Therapeutics Inc.$78
- Seagen Inc.$75
- Sanofi-aventis U.S. LLC$50
- Eisai Inc.$47
- plus $40 from 2 others
Across 33 payments — averaging $29,746 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$435K
- Eli Lilly$357K
- Puma Biotechnology, Inc.$108K
- E.r. Squibb & Sons, L.L.C.$57K
- Jazz Pharmaceuticals Inc.$25K
What the payments were for
- Consulting fees$3,81088%
- Food & beverage$3448%
- Education$1554%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $3,912 |
| AstraZeneca | 2 | $107 |
| Stemline Therapeutics Inc. | 2 | $78 |
| Seagen Inc. | 1 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $50 |
| Eisai Inc. | 2 | $47 |
| Bayer | 1 | $28 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$102
How this compares
$4,310 in reported general payments places this provider in the 40th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 18 | $2,617 |
| Letrozole | 53 | $1,166 |
| Anastrozole | 57 | $817 |
| Tamoxifen Citrate | 20 | $397 |
| Prochlorperazine Maleate | 27 | $267 |
| Dexamethasone | 32 | $257 |
| Ondansetron Hcl | 25 | $182 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.